Omnitrope (somatropin [rDNA origin]), is a recombinant human growth hormone product.
Omnitrope is indicated for long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, and for long-term replacement therapy in adults with GHD of either childhood- or adult onset.
Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended.
The recommended dosage at the start of therapy is not more than 0.04 mg/kg/week. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to a maximum of 0.08 mg/kg/week, depending upon patient tolerance of treatment. Clinical response, side effects, and determination of age-adjusted serum IGF-I may be used as guidance in dose titration. This approach will tend to result in weight-adjusted doses that are larger for women compared with men and smaller for older and obese patients.